Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, HiberCell Partner to Develop Companion Diagnostic Test for Oncology Immunotherapy

NEW YORK ─ Boulder, Colorado-based Biodesix on Wednesday announced an agreement with HiberCell to conduct further development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic test.

As part of the agreement, Biodesix will develop a CDx test to select patients for enrollment in HiberCell’s future registrational clinical trials. In an initial program, the ELISA-based CDx will be validated in Biodesix’s New York State CLEP-approved and CLIA-accredited lab.

The CDx is being designed to test for Anti-β Glucan IgG antibody expression in breast and melanoma serum samples to assess cancer patients’ eligibility for Imprime PGG therapy, Biodesix said.

Financial and other terms of the partnership were not disclosed.

While New York City-based HiberCell is developing a portfolio of therapies for patients living with recurrent metastatic disease, Biodesix develops diagnostic tests by combining multi-omic methods through artificial intelligence.

The partnership with Biodesix would further enable HiberCell's patient stratification capabilities for Imprime PGG, Alan Rigby, cofounder and CEO of HiberCell, said in a statement.

Imprime PGG is an innate immune activator that binds and agonizes dectin-1 to activate innate and adaptive immunity and enhance the immune response against tumors.